Oncology Reviews最新文献

The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma. MET信号通路在骨肉瘤靶向治疗中的作用及研究进展。

IF 3.1

Oncology Reviews Pub Date : 2025-06-17 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1615111

Qilong Su, Jingyu Hou, Xinhui Du, Fan Zhang, Panhong Zhang, Bangmin Wang, Weitao Yao

{"title":"The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma.","authors":"Qilong Su, Jingyu Hou, Xinhui Du, Fan Zhang, Panhong Zhang, Bangmin Wang, Weitao Yao","doi":"10.3389/or.2025.1615111","DOIUrl":"10.3389/or.2025.1615111","url":null,"abstract":"MET, a receptor tyrosine kinase proto-oncogene and the specific receptor for hepatocyte growth factor (HGF), plays a critical role in the initiation and progression of osteosarcoma (OS) through sustained pathway activation. Aberrant activation of MET has been shown to trigger multiple downstream signalling pathways, including RAS-ERK, PI3K-AKT, and STAT3, which are essential for OS cell proliferation, invasion, differentiation, and drug resistance. In recent years, significant progress has been made in the development of small-molecule inhibitors and specific antibodies targeting MET for OS therapy. The use of combination therapy as a treatment strategy involves the use of MET inhibitors in conjunction with chemotherapy, immunotherapy, and other targeted therapies. This approach has the potential to overcome resistance and improve therapeutic efficacy. This review summarises the mechanisms of MET signalling in OS, with a focus on the progress of MET-targeted therapies and their combination with other therapeutic strategies. The study provides valuable insights into future research directions, offering novel perspectives on the role of MET as a therapeutic target in OS.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1615111"},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144541632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colorectal cancer in south sulawesi: a case-control study for nongenetic risk factors. 南苏拉威西的结直肠癌：非遗传危险因素的病例对照研究。

IF 3.1

Oncology Reviews Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1589655

Upik A Miskad, Matthew Martianus Henry, Carissa Ikka Pardamean, Arif Budiarto, Akram Irwan, James W Baurley, Irawan Yusuf, Bens Pardamean

{"title":"Colorectal cancer in south sulawesi: a case-control study for nongenetic risk factors.","authors":"Upik A Miskad, Matthew Martianus Henry, Carissa Ikka Pardamean, Arif Budiarto, Akram Irwan, James W Baurley, Irawan Yusuf, Bens Pardamean","doi":"10.3389/or.2025.1589655","DOIUrl":"10.3389/or.2025.1589655","url":null,"abstract":"Background: This study analyzed the nongenetic risk factors that contributed to colorectal cancer (CRC) incidence in the South Sulawesi population through a case-control study.Methods: The sample consisted of 89 cases and 84 controls, aged between 19-86, with 99 males and 74 females from different ethnic groups. Univariate analysis was carried out using chi-square, Fisher's exact test, <math><mrow><mi>t</mi></mrow> </math> -test, and Mann-Whitney U test. Significant nongenetic risk factors were selected through the logit model L1 regularization, adjusted for age, gender, and ethnicity. The analyzed risk factors were the patient's weight, height, body mass index (BMI), defecation location, exercise habit, smoking habit, marital status, occupation, education level, and distance to the nearest health center. The estimated odds ratio from the logit model was used to analyze the significance of the selected risk factors.Results: The significant risk factors from the logit model were smoking habit, education level, marital status, distance to the nearest health center, and weight. CRC cases were more likely to have lower education (OR = 1.819, 95% CI 1.354-2.443), residing in remote areas (OR = 1.44, 95% CI 1.17-1.772), experiencing decreasing weight (OR = 1.03, 95% CI 1.013-1.048). Controls were more likely to be non-smokers (OR = 0.325, 95% CI 0.149-0.707) and unmarried (OR = 0.161, 95% CI 0.036-0.716).Conclusion: The study determined that other nongenetic risk factors, including education level, distance to the nearest health center, weight, smoking habit, and marital status, contributed to the CRC incidence within the South Sulawesi population. The study emphasized the importance in accounting for these risk factors for further, targeted CRC preventions.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1589655"},"PeriodicalIF":3.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer. 简要回顾Lynch综合征：了解子宫内膜癌和结直肠癌之间的双重癌症风险。

IF 3.1

Oncology Reviews Pub Date : 2025-05-16 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1549416

Sneha Pallatt, Sibin Nambidi, Subhamay Adhikary, Antara Banerjee, Surajit Pathak, Asim K Duttaroy

{"title":"A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer.","authors":"Sneha Pallatt, Sibin Nambidi, Subhamay Adhikary, Antara Banerjee, Surajit Pathak, Asim K Duttaroy","doi":"10.3389/or.2025.1549416","DOIUrl":"10.3389/or.2025.1549416","url":null,"abstract":"Lynch syndrome (LS) is an autosomal dominant disorder caused by germline mutations in DNA mismatch repair (MMR) genes. These mutations result in frameshift alterations, leading to the accumulation of errors within microsatellites. Individuals with LS have an elevated risk of developing colorectal and distant malignancies, including endometrial cancer (EC), which is one of the most common cancer associated with LS. Despite its significance, the association between EC and LS is often underexplored. Given the slow progression of colorectal cancer (CRC), there is an opportunity for early detection and intervention, which can aid in reducing both incidence and mortality through the identification and management of pre-malignant lesions and early-stage tumors in colorectum/endometrium. Recognizing individuals with a heightened risk of CRC is essential for implementing personalized screening strategies. This review summarizes the original research work on LS to find out the correlation of CRC following an endometrial cancer diagnosis in individuals with MMR gene mutations, may involve refine treatment strategies and moreover this review may help clinicians and researchers to get an up-to date information on LS and its advanced treatment possibilities.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1549416"},"PeriodicalIF":3.1,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of UGT1A1 polymorphism in the management of colorectal cancer. UGT1A1多态性在结直肠癌治疗中的作用

IF 3.1

Oncology Reviews Pub Date : 2025-05-13 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1547904

Elham Babadi, Kamran Roudini, Kianmehr Aalipour, Olatunji B Alese

{"title":"The role of UGT1A1 polymorphism in the management of colorectal cancer.","authors":"Elham Babadi, Kamran Roudini, Kianmehr Aalipour, Olatunji B Alese","doi":"10.3389/or.2025.1547904","DOIUrl":"10.3389/or.2025.1547904","url":null,"abstract":"Colorectal cancer is a leading cause of cancer related deaths among patients worldwide, necessitating the development of more effective and tolerable therapies. Topoisomerase I inhibitors such as Irinotecan are integral components of chemotherapy regimens used in the management of colorectal, as well as esophageal, gastric, biliary tract, pancreatic, neuroendocrine, small bowel and anal carcinomas. Efficacy and toxicity of these regimens are however impacted by metabolism via the UGT1A1 pathways. This literature review provides a comprehensive overview of UGT1A1 polymorphism in patients with colorectal cancer, including recent developments and the future landscape. Recent literature elucidating the roles of oncogenes and predictive biomarkers on anti-cancer drugs and UGT1A1 genotypes are described. The lack of consensus in the clinical management of patients with colorectal cancer were also explored in depth. A comprehensive search was performed in multiple databases (including PubMed, Embase, Web of Science, Scopus, Research gate, and Google Scholar) to identify relevant articles published up to January 2024. A total of 79 clinical studies were included in this review. The epidemiology and frequency of UGT1A1 genes polymorphisms by race, gender, ethnicity, geographic location and stage of the cancer were correlated with drug metabolism, toxicity, and survival outcomes. The tole of UGT1A1 as a prognostic and predictive biomarker, including existing challenges in clinical application were also discussed extensively.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1547904"},"PeriodicalIF":3.1,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144160721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting mitochondrial ClpP: structural insights and therapeutic potential of ClpP agonists in cancer therapy. 靶向线粒体ClpP: ClpP激动剂在癌症治疗中的结构见解和治疗潜力。

IF 3.1

Oncology Reviews Pub Date : 2025-05-06 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1567860

Mowei Kong, Yang Yu, Shuai Shao, Chunxiang Zhang

{"title":"Targeting mitochondrial ClpP: structural insights and therapeutic potential of ClpP agonists in cancer therapy.","authors":"Mowei Kong, Yang Yu, Shuai Shao, Chunxiang Zhang","doi":"10.3389/or.2025.1567860","DOIUrl":"10.3389/or.2025.1567860","url":null,"abstract":"Mitochondrial \"powerhouses\" play a central function in cellular metabolism and energy generation. Their dysregulation is directly correlated with a myriad of diseases, among them cancer. The serine protease ClpP, accompanied by its cochaperone ClpX, is a principal homeostatic regulator in mitochondrial function by degrading aberrant proteins in order to preserve mitochondrial integrity. Recently, evidence suggests ClpP is overexpressed in many cancer cells and, as such, is an appealing target for drug therapy. In this review, current information about the structure, physiological function, and therapeutic promise of mitochondrial ClpP in oncology is summarized. We provide an overview about the mechanistic rationale behind ClpP agonists as novel anticancer drugs, their regulation in cell signal transduction, and the major challenge in the creation of small molecules that specifically activate human ClpP, but not bacterial ClpP. The review highlights the therapeutic promise of ClpP agonists as a novel approach in cancer therapy, presenting their prospective potential for cancer treatment by focusing on an unexplored mitochondrial target.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1567860"},"PeriodicalIF":3.1,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacies of radiotherapy in rectal cancer patients treated with total mesorectal excision or other types of surgery: an updated meta-analysis. 放疗在直肠癌患者全肠系膜切除或其他类型手术治疗中的疗效：一项最新的荟萃分析。

IF 3.1

Oncology Reviews Pub Date : 2025-05-01 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1567818

Wenshu Wang, Runyuan Zhao, Xi Liang, Manjun Liu, Haiyan Bai, Jianli Ge, Binxi Yao, Zheng Zhi, Jianming He

{"title":"Efficacies of radiotherapy in rectal cancer patients treated with total mesorectal excision or other types of surgery: an updated meta-analysis.","authors":"Wenshu Wang, Runyuan Zhao, Xi Liang, Manjun Liu, Haiyan Bai, Jianli Ge, Binxi Yao, Zheng Zhi, Jianming He","doi":"10.3389/or.2025.1567818","DOIUrl":"https://doi.org/10.3389/or.2025.1567818","url":null,"abstract":"Background: An updated meta-analysis was conducted to evaluate the efficacy of radiotherapy in rectal cancer patients treated with total mesorectal excision (TME) or other types of surgery (non-TME-only).Methods: The PubMed, Cochrane Library, and CNKI databases were searched. Data on overall survival (OS) were extracted.Results: Hazard ratios (HRs) for OS associated with preoperative radiotherapy, preoperative long-course concurrent chemoradiotherapy (LCCRT), preoperative radiotherapy alone, and postoperative radiotherapy in patients treated with TME were 1.02 [95% CI: 0.92-1.14, P = 0.65], 1.04 [95% CI: 0.93-1.16, P = 0.47], 0.87 [95% CI: 0.61-1.25, P = 0.46], and 1.18 [95% CI: 0.91-1.52, P = 0.20], respectively. HRs for OS associated with preoperative radiotherapy, preoperative LCCRT, preoperative radiotherapy alone, preoperative long-course RT (LCRT), and preoperative short-course radiotherapy (SCRT) in patients treated with non-TME-only surgery were 0.85 [95% CI: 0.79-0.90, P < 0.00001], 0.77 [95% CI: 0.63-0.94, P = 0.009], 0.86 [95% CI: 0.80-0.92, P < 0.0001], 0.83 [95% CI: 0.73-0.95, P = 0.005], and 0.84 [95% CI: 0.77-0.91, P= <0.0001], respectively. The HR for postoperative radiotherapy in patients treated with non-TME-only surgery was 1.08 [95% CI: 0.84-1.39, P = 0.57].Conclusion: Preoperative radiotherapy, regardless of the regimen, improves the OS in patients treated with non-TME-only surgery, but not in those treated with TME. Postoperative radiotherapy does not improve OS.Advances in knowledge: This meta-analysis will serve as a reference for decision-making in multidisciplinary approaches for rectal cancer patients.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1567818"},"PeriodicalIF":3.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Historical view of the effects of radiation on cancer cells. 辐射对癌细胞影响的历史观点。

IF 3.1

Oncology Reviews Pub Date : 2025-04-30 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1527742

Saskia Hazout, Christoph Oehler, Daniel R Zwahlen, Daniel Taussky

{"title":"Historical view of the effects of radiation on cancer cells.","authors":"Saskia Hazout, Christoph Oehler, Daniel R Zwahlen, Daniel Taussky","doi":"10.3389/or.2025.1527742","DOIUrl":"https://doi.org/10.3389/or.2025.1527742","url":null,"abstract":"Introduction: Since Röntgen's discovery of X-rays in 1895, advancements in radiobiology have significantly shaped radiotherapy practices. This historical review traces the evolution of radiobiological theories and their impacts on current therapeutic strategies.Materials and methods: Databases such as PubMed were utilized to trace the evolution of concepts in radiobiology.Results/discussion: One of the first theories concerning the effect of radiation was Dessauer's target theory, introduced in the 1920s. He found that damage to critical molecular cellular targets leads to cell death. In the early 20th century, Muller contributed to the understanding of DNA structure and radiation-induced mutations, highlighting theories on the impact of radiation on genetic material and cellular damage. In 1972, Kellerer and Rossi introduced the theory of dual radiation action, which explains that ionizing radiation induces sequential damage to DNA, starting with single-strand breaks and progressing to irreparable double-strand breaks. Recent advances have enhanced the understanding of the effects of radiation on the microenvironment and immune responses, thereby improving therapeutic outcomes. The significance of the sigmoid dose-response curve and the initial shoulder effect were recognized early, leading to theoretical models such as the multitarget single-hit, linear-quadratic and repair-misrepair models. The history of fractionation and the 4R/5R principles have informed today's ultrahigh fractionation techniques, including single doses of approximately 20 Gy.Conclusion: Although significant advances have been made toward understanding the effects of radiation on cancerous and healthy tissues, many clinical observations, such as the effects of very high doses or FLASH therapy, remain poorly understood.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1527742"},"PeriodicalIF":3.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The endocannabinoid system in cancer biology: a mini-review of mechanisms and therapeutic potential. 内源性大麻素系统在癌症生物学中的作用：机制和治疗潜力的综述。

IF 3.1

Oncology Reviews Pub Date : 2025-04-30 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1573797

Kaio Cezar Rodrigues Salum, Gabriel Brendo Alves Miranda, Alessandra Lima Dias, João Regis Ivar Carneiro, Patrícia Torres Bozza, Ana Carolina Proença da Fonseca, Tamara Silva

{"title":"The endocannabinoid system in cancer biology: a mini-review of mechanisms and therapeutic potential.","authors":"Kaio Cezar Rodrigues Salum, Gabriel Brendo Alves Miranda, Alessandra Lima Dias, João Regis Ivar Carneiro, Patrícia Torres Bozza, Ana Carolina Proença da Fonseca, Tamara Silva","doi":"10.3389/or.2025.1573797","DOIUrl":"https://doi.org/10.3389/or.2025.1573797","url":null,"abstract":"The Endocannabinoid System (ECS) plays a critical role in maintaining physiological homeostasis, influencing a range of processes such as neuroprotection, inflammation, energy metabolism, and immune responses. Comprising cannabinoid receptors (CB1 and CB2), endogenous ligands (endocannabinoids), and the enzymes responsible for their synthesis and degradation, the ECS has attracted increasing attention in cancer research. Cannabinoid receptor activation has been associated with the regulation of cancer-related processes, including cell proliferation, apoptosis, and angiogenesis, suggesting that the ECS may have a role in tumor progression and cancer treatment. Preclinical studies have shown that cannabinoids, through their interaction with CB1 and CB2 receptors, can inhibit tumor cell growth, induce programmed cell death, and suppress the formation of new blood vessels in various cancer models. Despite these encouraging findings, the clinical translation of ECS-targeted therapies remains in its early stages. The complexity of tumor heterogeneity, the variability in patient responses, and the challenges associated with the pharmacokinetics of cannabinoids are significant obstacles to the broader application of these findings in clinical settings. This review provides an overview of the current understanding of the ECS's involvement in cancer biology, focusing on key mechanisms by which it may influence carcinogenesis. Additionally, we discuss the therapeutic potential of targeting the ECS in cancer treatment, while highlighting the limitations and uncertainties that need to be addressed through ongoing research.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1573797"},"PeriodicalIF":3.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospects of engineered bacteria-assisted CAR T Cell therapy in gastrointestinal cancers. 工程细菌辅助CAR - T细胞治疗胃肠道肿瘤的前景。

IF 3.1

Oncology Reviews Pub Date : 2025-04-14 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1581856

Qingqing Zhang, Xiao Song, Junhong Liu, Xuejiao Zhou

引用次数: 0

Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. 治疗er阳性乳腺癌：目前fda批准的serm和serd及其作用机制的回顾

IF 3.1

Oncology Reviews Pub Date : 2025-04-10 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1564642

Nayoung Kim, Kiven Erique Lukong

{"title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action.","authors":"Nayoung Kim, Kiven Erique Lukong","doi":"10.3389/or.2025.1564642","DOIUrl":"https://doi.org/10.3389/or.2025.1564642","url":null,"abstract":"Breast cancer is one of the most significant causes of mortality among women and the second most prevalent cancer worldwide. Estrogen receptor (ER)-positive breast cancers are the most common molecular subtype of breast cancer, comprising about 70% of breast carcinoma diagnoses worldwide. Endocrine therapy is the foremost strategy for the treatment of ER-positive breast cancer. In the United States, the Food and Drug Administration (FDA) has approved endocrine therapies for ER-positive breast cancers that include selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators/degraders (SERDs) and aromatase inhibitors (AIs). The approved SERMS, tamoxifen, toremifene and raloxifene, are the gold-standard treatments. The only FDA-approved SERD available for treating ER and hormone-positive breast cancers is fulvestrant, and various generations of AIs, including exemestane, letrozole, and anastrozole, have also received FDA approval. Herein, we review the major FDA-approved SERMs and SERDs for treating ER-positive breast cancer, focusing on their mechanisms of action. We also explore molecular events that contribute to the resistance of these drugs to endocrine therapies and combinational strategies with drugs such as cyclin-dependant kinases 4/6 (CDK4/6) inhibitors in clinical trials to combat endocrine drug resistance.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1564642"},"PeriodicalIF":3.1,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0